Tag: filing

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the “Class Period”), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

MONTREAL and MCLEAN, Va., June 25, 2026 (GLOBE NEWSWIRE) -- NorthStar Earth & Space Inc. (“NorthStar” or the “Company”), a global leader in Space Situational Awareness (“SSA”) and Space Domain Awareness (“SDA”), and Viking Acquisition Corp. I (“Viking”) (NYSE: VACI), a special purpose acquisition company, announced today the public filing of their joint registration statement on Form F-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) in connection with their proposed business combination (the “Business Combination Agreement”) announced on April 17, 2026, available here.

Stewart Bain, Founder and Chief Executive Officer of NorthStar, said, “The public filing of our registration statement represents an important milestone in the process of becoming a public company. The market demand for NorthStar’s differentiated space-based intelligence platform requires accelerating our long-term growth strategy. Increased access to capital and global awareness, inherent with a public company, will enable us to expand capabilities and deepen customer support by delivering more critical insights to stakeholders through our services.”

Manchester, England, June 25, 2026 (GLOBE NEWSWIRE) -- In direct response to the increasingly sophisticated and predatory tactics utilized by global cybercriminals, the Finance Complaint List has officially announced the launch of its newly integrated financial protection and recovery ecosystem. This comprehensive platform introduces an advanced, privacy-first global fraud reporting database alongside specialized asset recovery pathways. The unified framework is designed to safeguard traditional investments and personal savings, offering an unprecedented end-to-end defense mechanism for retail investors and everyday consumers alike.

NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the Company (the “Common Shares”) at an offering price of US$4.85 per Common Share, for aggregate gross proceeds of US$50 million (the “Offering”).